-
FDA approves Takeda's tyrosine kinase inhibitor ALUNBRIG (brigatinib), first-line treatment of ALK-positive metastatic non-small cell lung cancer patients
Time of Update: 2020-05-29
Takeda announced that the U.S Food and Drug Administration (FDA) has approved its tyrosine kinase inhibitor (TKI) ALUNBRIG (brigatinib) for metastatic lymphoma kinase-positive (ALK-positive) patien
-
Cell Death Dis: E2F1 Mediated DDX11 Transcription Activation Promotes hepatocellular Carcinoma Development through PI3K/AKT/mTOR Pathway
Time of Update: 2020-05-29
Hepatocellular carcinoma (HCC) is a primary liver malignant tumor, which is the third leading cause of cancer-related death Often when curative treatment is not possible, patients are diagnosed wit
-
Professor Wang Xiaojia: More affordable, Sidabenamine offers breast cancer patients more treatment options
Time of Update: 2020-05-29
On April 10, 2020, the 2020 edition of the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnostic Guidelines was released in a new way through "cloud" remote video conferencing In thi
-
Nature Cancer: New Target spree for cancer immunotherapy - c-Rel (Professor Li Bin comments)
Time of Update: 2020-05-29
Immune checkpoint blocking offers new hope for the treatment of multiple cancers, however, T-cell-specific checkpoint inhibitors are not effective in all cancer patients In a paper published May 18
-
Blood: LUBAC promotes lymphoma formation by blocking DNA damage-induced cell death
Time of Update: 2020-05-29
Linear Ubiquital chain assembly complex (LUBAC) is a key regulatory factor for the NF-kB signaling pathway LUBAC's catalytic sub-nucleotide polymorphism was concentrated in activated B-cell-like di
-
Blood: Molecular mechanisms of B-ALL hyperxaid cells with filament division and chromosomal defects
Time of Update: 2020-05-29
B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, and hyper-hyperphee (HyperD) is the most common subtype of B-ALL in children Although HyperD is the initial carcinog
-
Cell Death Dis: LINC01116 Collected by IL-1 beta glioma proliferation and neutrophils
Time of Update: 2020-05-29
Glioma is one of the most common intracranial malignancies Glioblastoma (stage IV glioma) is the most malignant type of glioma, the total survival time of patients is about 14 months, only less tha
-
Clin Cancer Res: The results of the first phase of the car-T cell treatment of advanced hepatocellular carine in GPC3 were announced, with initial and significant results
Time of Update: 2020-05-29
Recently, the team of Professor Zibo, Director of the Oncology Intervention Department of Renji Hospital affiliated with Shanghai Jiaotong University School of Medicine, and Professor Li Zonghai of
-
NAT GENET: CRISPR gene editing has potential carcinogenicity
Time of Update: 2020-05-29
Cas9 is usually introduced into cell lines to achieve CRISPR-Cas9-mediated genome editing Recently, researchers explored the genetic and transcriptional consequences of Cas9 expression itself a g
-
Cell Death Dis: CtBP determines fate of ovarian cancer cells by suppressing DRs
Time of Update: 2020-05-29
High-level plasma ovary cancer (HGSOC) is a complex heterogeneous disease that accounts for 70% of epithelial ovarian cancer and is still the deadliest gynecological malignancies The main treatment
-
Sanofi/Regenerative PD-1 monoantia Libtayo shows significant benefits in base cell carcinoma
Time of Update: 2020-05-29
Sanofi and regenerative PD-1 monolibalibalib (cemiplimab) show a 'clinically meaningful and long-lasting response' in base cell carcinoma (BCC), which currently has no approved treatment The two
-
Real-world data! PD1 drug resistance continues to benefit!
Time of Update: 2020-05-29
introduction sits authors Qiu Lixin works in oncology medicine at Fudan University's Affiliated Oncology Hospital Mainly engaged in gastric cancer, bowel cancer and other malignant tumors of
-
29-year-old girl, there is little left of herthopedic bones...
Time of Update: 2020-05-29
Baby's head-sized tumor, the erosion of the tibia disappeared, covered with nerves, blood vessels of the "surgical exclusion zone", a 29-year-old young life, a "I want to take care of myself, do no
-
EMA begins review of Morpho Sys CD19 monoastytasitamab to treat lymphoma
Time of Update: 2020-05-29
The European Medicines Agency (EMA) has begun a review of MorphoSys targeting CD19's monophonoid tafasitamab (MOR208), which, if approved, could pose a challenge to Novartis and Gilead's CAR-T ther
-
Junshi Bio's PD-1 single anti-Trump treatment of urinary skin cancer, supplementary new drug application accepted by NMPA
Time of Update: 2020-05-29
Junshi Biosannounc signed that the National Drug Administration (NMPA) has accepted its PD-1 single anti-triprib supplementary new drug application (sNDA) for second-line treatment for patients wi
-
ASCO 2020: 10-year follow-up results for 3 or 1 year Imatinib-assisted treatment of high-risk gastrointestinal mesoplasmic tumors
Time of Update: 2020-05-29
Gastrointestinal mesothelioma (GIST) is a common type of sarcoma, and several factors closely related to prognosis are tumor nuclei, tumor size, site and tumor rupture, the current risk classificat
-
Another indication approved! Odivo (Navuliyu monoantigen) combined with Ipitaph mono-resistance and limited course of chemotherapy for first-line treatment in patients with metastasis or recurrent non-small cell lung cancer
Time of Update: 2020-05-29
On May 26, 2020, The U.S Food and Drug Administration (FDA) has approved Odivo (Navuliyu monoantigen, 360 mg) combined with Epiwood monoantigen (1mg/kg, intravenous) and two cycles of platinum-cont
-
J Natl Cancer Inst: Y chromosome low expression is susceptible to cancer! Study found that extremely low expression of The Y chromosome was associated with a 2.66-fold increase in the incidence of cancer in men
Time of Update: 2020-05-29
Recent lying studies by Alejandro C?ceres and Juan R Gonz?lez of the Global Health Institute in Barcelona have found that extreme lybidonising (EDY) of genes on the Y chromosome is associated with
-
Academic Frontiers . . . Yang Xuejun team of Tianjin General Hospital found that the new drug ACT001 new mechanism to inhibit glioma growth Phase II clinical trial will be launched
Time of Update: 2020-05-29
Recently, Professor Yang Xuejun of Neurosurgery at Tianjin Medical University General Hospital team edged the team of Professor Michael Lim of Johns Hopkins University School of Medicine and membe
-
Professor Zhang Qingxuan interview: From lymphoma to breast cancer, HDAC inhibitor Sidabenamine has a breakthrough in solid tumors
Time of Update: 2020-05-29
Sidabenamine is the first epigenetic regulatory drug with China's independent intellectual property rights, approved five years ago to treat lymphoma, has caused a sensation in the industry Based o
